Cel-Sci Corporation (NYSEAMERICAN:CVM) Short Interest Up 172.4% in July

Cel-Sci Corporation (NYSEAMERICAN:CVM) was the target of a significant growth in short interest in July. As of July 15th, there was short interest totaling 718,008 shares, a growth of 172.4% from the June 30th total of 263,542 shares. Based on an average daily trading volume, of 399,680 shares, the days-to-cover ratio is presently 1.8 days. Currently, 4.6% of the company’s stock are sold short.

Institutional Trading of Cel-Sci

Several institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC grew its position in Cel-Sci by 133.0% during the first quarter. Renaissance Technologies LLC now owns 35,890 shares of the company’s stock valued at $115,000 after purchasing an additional 20,484 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Cel-Sci during the 4th quarter valued at $66,000. State Street Corp grew its holdings in shares of Cel-Sci by 9.9% during the 4th quarter. State Street Corp now owns 25,570 shares of the company’s stock valued at $134,000 after acquiring an additional 2,300 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Cel-Sci in the fourth quarter worth $83,000. Finally, HRT Financial LP purchased a new stake in shares of Cel-Sci during the fourth quarter worth $60,000. 12.08% of the stock is currently owned by institutional investors and hedge funds.

Cel-Sci Price Performance

Cel-Sci stock remained flat at $1.18 during mid-day trading on Monday. The company had a trading volume of 146,707 shares, compared to its average volume of 274,073. The stock’s 50-day moving average is $1.26 and its 200 day moving average is $3.12. The firm has a market cap of $20.63 million, a P/E ratio of -0.12 and a beta of 0.64. The company has a current ratio of 0.60, a quick ratio of 0.54 and a debt-to-equity ratio of 0.64. Cel-Sci has a 1 year low of $0.89 and a 1 year high of $13.48.

Cel-Sci (NYSEAMERICAN:CVM) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.67) EPS for the quarter.

Cel-Sci Company Profile

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.